z-logo
open-access-imgOpen Access
Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
Author(s) -
Pitoia Fabián
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3900
Subject(s) - medicine , papillary thyroid cancer , trk receptor , thyroid cancer , refractory (planetary science) , fusion gene , thyroid , cancer research , surgery , oncology , pathology , gene , neurotrophin , receptor , physics , astrobiology , biochemistry , chemistry
Larotrectinib, a highly selective TRK inhibitor, was administered to a patient with rapidly progressing radioactive iodine‐refractory papillary NTRK3 fusion‐positive thyroid cancer. The patient achieved a durable (sustained for 11 months) complete response after 2 months of treatment and complete intracranial responses in metastatic brain lesions after 7 months of treatment. Larotrectinib may provide a therapeutic route for patients with RAI‐R‐differentiated thyroid cancer who might otherwise have few treatment options.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here